Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 2, 2008, Pages 534-542

  Kruser, Tim J ^a   Armstrong, Eric A ^a   Ghia, Amol J ^a   Huang, Shyhmin ^a   Wheeler, Deric L ^a   Radinsky, Robert ^b   Freeman, Daniel J ^b   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b AMGEN INC   (United States)

Author keywords

EGFR; Epidermal growth factor receptor; Panitumumab; Radiation

Indexed keywords

ANIMAL CELL CULTURE; ANTIBODIES; ASSAYS; BIOACTIVITY; BIOLOGICAL MATERIALS; BIOLOGICAL ORGANS; CELL CULTURE; CELL DEATH; CELLS; CHEMICAL REACTIONS; CYTOLOGY; DAMAGE DETECTION; DNA; GENES; MONOCLONAL ANTIBODIES; NUCLEIC ACIDS; ORGANIC ACIDS; PEPTIDES; RADIATION;

DNA DAMAGES; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; NON-SMALL-CELL LUNG CANCER; PANITUMUMAB;

CELL GROWTH;

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN G; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MOUTH FLOOR; MOUTH NEOPLASMS; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 51449117743     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.06.1490     Document Type: Article

References (23)

1. Hynes N.E., and Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
2. Schmidt-Ullrich R.K., Valerie K.C., Chan W., et al. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29 (1994) 813-819
3. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 (1999) 2884-2890
4. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
5. Raben D., Helfrich B., Chan D.C., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11 (2005) 795-805
6. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
7. Foon K.A., Yang X.D., Weiner L.M., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58 (2004) 984-990
8. van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
9. Wirth L.J., Posner M.R., Tishler R.B., et al. Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. Pro Am Soc Clin Oncol 25 (2007) 6081
10. Burma S., Chen B.P., Murphy M., et al. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276 (2001) 42462-42467
11. Dittmann K., Mayer C., and Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol 76 (2005) 157-161
12. Bentzen S.M. Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 79 (2003) 581-585
13. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
14. Huang S.M., Li J., Armstrong E.A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (2002) 4300-4306
15. Song J.I., and Grandis J.R. STAT signaling in head and neck cancer. Oncogene 19 (2000) 2489-2495
16. Alvarez J.V., Greulich H., Sellers W.R., et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66 (2006) 3162-3168
17. Amorino G.P., Hamilton V.M., Valerie K., et al. Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 13 (2002) 2233-2244
18. Akashi Y., Okamoto I., Iwasa T., et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 98 (2008) 749-755
19. Mandic R., Rodgarkia-Dara C.J., Zhu L., et al. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 580 (2006) 4793-4800
20. Wheeler D., Ghia A., Kruser T., et al. Src family kinase and the EGFR cooperate in acquired resistance to cetuximab. Pro Am Assoc Cancer Research (2008) #2453
21. Perrotte P., Matsumoto T., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5 (1999) 257-265
22. Kurai J., Chikumi H., Hashimoto K., et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13 (2007) 1552-1561
23. Zhang W., Gordon M., Schultheis A.M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25 (2007) 3712-3718